Relationship Between Antimetabolite Toxicity and Pharmacogenetics in Turkish Cancer Patients |
Dogan, Mutlu
(Dept of Medical Oncology, School of Medicine, Ankara University)
Karabulut, Halil G. (Dept of Medical Genetics, School of Medicine, Ankara University) Tukun, Ajlan (Dept of Medical Genetics, School of Medicine, Ankara University) Demirkazik, Ahmet (Dept of Medical Oncology, School of Medicine, Ankara University) Utkan, Gungor (Dept of Medical Oncology, School of Medicine, Ankara University) Yalcin, Bulent (Dept of Medical Oncology, School of Medicine, Ankara University) Dincol, Dilek (Dept of Medical Oncology, School of Medicine, Ankara University) Akbulut, Hakan (Dept of Medical Oncology, School of Medicine, Ankara University) Icli, Fikri (Dept of Medical Oncology, School of Medicine, Ankara University) |
1 | Campalani E, Arenas M, Marinaki M, et al (2007). Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol, 127, 1860-7. DOI |
2 | Dervieux T, Meshkin B, Neri B (2005). Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. Mutat Res, 573, 180-94. DOI |
3 | Goyette P, Pai A, Milos R, et al (1998). Gene structure of human and mouse methylenetetrahydrofolate reductase. Mamm Genome, 9, 652-6. DOI ScienceOn |
4 | Gross E, Busse B, Riemenschneider M, et al (2008). Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS One, 3, e4003, 1-7. |
5 | Kantar M, Kosova B, Cetingul N, et al (2009). Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma, 50, 912-7. DOI ScienceOn |
6 | Lopez-Cima MF, Gonzalez-Arriaga P, García-Castro L, et al (2007). Polymorphisms in XPC, XPD, XRCC1, and XRCC3 DNA repair genes and lung cancer risk in a population of northern Spain. BMC Cancer, 7, 162-73. DOI |
7 | Magne N, Etienne-Grimaldi MC, Cals L, et al (2007). Dihydropryrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity. Br J lin Pharmacol, 64, 237-40. DOI |
8 | Meta-Analysis Group in Cancer (1998). Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol, 16, 3537-41. |
9 | Sliwinski T, Krupa R, Wisniewska-Jarosinska M et al (2009). Common polymorphisms in the XPD and hOGG1 genes are not associated with the risk of colorectal cancer in a Polish population. Tohoku J Exp Med, 218, 185-91. DOI |
10 | Sreeja L, Syamala VS, Syamala V, et al (2008). Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India. J Cancer Res Clin Oncol, 134, 645-52. DOI |
11 | Toffoli G, de Mattia E (2008). Pharmacogenetic relevance of MTHFR polymorphisms. Pharmacogenomics, 9, 1195-206. DOI |
12 | Van Kuilenburg AB, Haasjes J, Richel DJ, et al (2000). Clinical Implications of Dihydropyrimidine Dehydrogenase (DPD) Deficiency in Patients with Severe 5-Fluorouracil-associated Toxicity: Identification of New Mutations in the DPD Gene Clinical Cancer Research, 6, 4705-12. |
13 | Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH (2002). Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to dihydroprymidine dehydrogenase deficiency: high prevelance of the IVS14- 1G-A mutation. Int J Cancer, 101, 253-8. DOI |
14 | Van Kuilenburg AB (2004). Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer, 40, 939-50. DOI |
15 | Wang M, Gu D, Zhang Z, et al (2009). XPD polymorphisms, cigarette smoking, and bladder cancer risk: a meta-analysis. J Toxicol Environ Health A, 72, 698-05. DOI |